InterK Peptide Therapeutics is developing peptide-based immunotherapeutic candidates based on the activation of a single kinase which leads to the production of cytokines required to maintain an adequate immune response.

These compounds have been shown to exert their beneficial effect not only on normal immune cells but also on immune cells that have become exhausted.

The Company’s immediate focus is to evaluate the contribution its compounds may make in the field of immuno-oncology used either alone or as combinatorial/adjunctive therapy.

InterK compounds may also have wider application across a range of non-cancer diseases and conditions where restoration of a compromised immune system or enhancement of function by normal immune cells is warranted.

Contact Us
Phone +61 418 212 254

Preclinical development of peptide based therapeutic candidates in Sydney Australia

Share this page